Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponsegromab - Pfizer

Next Previous
Drug Profile

Ponsegromab - Pfizer

Alternative Names: PF 06946860

Latest Information Update: 04 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Appetite stimulants; Heart failure therapies; Monoclonal antibodies
  • Mechanism of Action Growth differentiation factor 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cachexia
  • Discontinued Heart failure

Most Recent Events

  • 25 May 2025 Pfizer plans a phase IIb/III trial in Cachexia (SC)(NCT06989437)
  • 23 Apr 2025 Pfizer completes a Phase II trial in Cachexia in Australia, Bulgaria, Canada, China, France, Hungary, Japan, Poland, Slovakia, Spain, Taiwan and USA (SC) (NCT05546476)
  • 14 Apr 2025 Pfizer terminates the phase-II GARDEN TIMI 74 trial in Heart failure in Australia, Canada, China, Czechia, Germany, Hungary, Japan, Poland, Spain, the UK and US(SC, Injection), following a prespecified interim analysis and in consultation with the independent Data Monitoring Committee, due to outcomes related to symptoms, function, quality of life, and safety(NCT05492500)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top